- Saudi crown prince says no Israel ties without Palestinian state
- Canada to further cut international student, foreign worker permits
- YouTube launches new TV-focused tools for creators
- White Sox heading for worst season in MLB history
- China the top challenge in US history: senior diplomat
- Hong Kong democracy tycoon's son warns time running out
- New migraine drugs no better than cheap painkillers: big study
- Sean 'Diddy' Combs again denied bail in sex trafficking case
- Brewers clinch division title as MLB playoff race heats up
- Man City blunted by 'giant' Inter in Champions League stalemate
- US stocks dip despite larger Fed interest rate cut
- Man City held by Inter as PSG pinch win in Champions League
- All Blacks recall Beauden Barrett for Australia Test
- Fears of all-out war as new Lebanon device blasts kill 20, wound 450
- Spurs late show saves Postecoglou blushes at Coventry
- PSG snatch late goal to beat Champions League debutants Girona
- Gittens' late double gives Dortmund Champions League win at Brugge
- Man City blunted by Inter in Champions League stalemate
- Hidden talent: French Olympic star Marchand opts for disguise
- MrBeast named in California lawsuit over 'Beast Games' show
- Gauff splits with Gilbert as coach after 14-month run
- Hundreds of thousands at risk in Sudan's El-Fasher: UN
- Harvey Weinstein pleads not guilty to new sex crime charge
- Venezuelan opposition candidate says letter conceding election was coerced
- Ukraine official claims Russian advance in Kursk has been 'stopped'
- X update allows app to bypass Brazil ban: internet providers
- Fears of all-out war as new Lebanon device blasts kill 14, wound 450
- US Fed makes aggressive rate cut, weeks before election
- Arsenal's Odegaard faces lengthy injury absence
- India coal expansion risks massive methane growth: report
- China the top challenge in US history, top diplomat says
- US Fed makes larger half-point cut in first reduction since 2020
- Ronaldo's Al Nassr appoint former AC Milan boss Pioli
- Ainslie 'relieved' as British book place in Louis Vuitton Cup final
- Struggling Roma replace sacked icon De Rossi with Ivan Juric
- Women's NBA will add 15th team in Portland in 2026
- Brazil fires need harsher punishment: environmental police boss
- Boeing to start large temporary furloughs amid Seattle strike
- Fears of all-out war as new Lebanon device blasts kill nine, wound 300
- 'Emergency' declared over falling UK butterfly numbers
- McIlroy outlines threats to golf peace deal
- Stock markets, dollar slip before US rate decision
- Russian advance in Kursk 'stopped': Ukraine official to AFP
- UN members demand end to 'unlawful' Israeli occupation of Palestinian territories
- Snapchat pushes 'safer' platform image, but not everyone agrees
- Three dead, 100 wounded in new wave of Lebanon device explosions
- So where does the oceans' plastic waste come from?
- Allied war heroes buried in Netherlands... 80 years on
- Marsh coy over Australia's choice to open alongside Head
- New London sculpture pays tribute to trans community
RBGPF | 5.79% | 60.5 | $ | |
CMSC | 0.02% | 25.055 | $ | |
RYCEF | 1.37% | 6.55 | $ | |
CMSD | -0.12% | 24.98 | $ | |
GSK | -0.31% | 42.43 | $ | |
SCS | 0.71% | 14.11 | $ | |
RIO | -0.02% | 62.91 | $ | |
BTI | -0.34% | 37.88 | $ | |
NGG | -0.46% | 70.05 | $ | |
RELX | -0.82% | 47.37 | $ | |
VOD | 0.49% | 10.23 | $ | |
BCC | 1.33% | 137.06 | $ | |
JRI | 0.45% | 13.44 | $ | |
BCE | 3.09% | 35.61 | $ | |
BP | -0.37% | 32.43 | $ | |
AZN | 0.06% | 78.58 | $ |
WHO 'strongly recommends' Pfizer's Covid pill
The World Health Organization said Friday it "strongly recommended" Pfizer's Covid-19 antiviral pill Paxlovid for patients with milder forms of the disease who were still at a high risk of hospitalisation.
However the UN agency warned it was "extremely concerned" that the inequality in access seen with Covid vaccines would again leave low- and middle-income countries "pushed to the end of the queue".
US pharma giant Pfizer's combination of nirmatrelvir and ritonavir was the "superior choice" of treatment for unvaccinated, elderly or immunocompromised people with Covid, the WHO's experts said in the BMJ medical journal.
For the same patients, the WHO also made a "conditional (weak) recommendation" of the antiviral drug remdesivir made by US biotech firm Gilead -- which it had previously recommended against.
The WHO recommended Paxlovid over remdesivir, as well as over Merck's molnupiravir pill and monoclonal antibodies.
Pfizer's oral treatment prevents hospitalisation more than the "available alternatives, has fewer concerns with respects to harms than molnupiravir, and is easier to administer than intravenous remdesivir and antibodies," the WHO's experts said.
The new recommendation was based on the findings of two trials involving almost 3,100 patients which showed that Paxlovid reduced the risk of hospital admission by 85 percent.
The trials also "suggested no important difference in mortality" and "little or no risk of adverse effects leading to drug discontinuation".
The recommendation applies to people over the age of 18, but not to pregnant or breastfeeding women.
It also does not apply to patients with a low risk of complications from the disease, because the benefit would be minimal.
The WHO's experts also declined to give an opinion for patients with severe forms of the disease, due to a lack of data.
- Limitations and inequities -
The WHO stressed the limitations of such antiviral treatments.
"The medicine can only be administered while the disease is at its early stages," they said.
This means the patients must quickly test positive and be prescribed the pill by a doctor -- all of which can pose obstacles for low- and middle-income countries, the WHO said.
Yet Covid pills have been seen as a potentially huge step in ending the pandemic as they can be taken at home, rather than in hospital.
Patients must start taking their Paxlovid pills within five days of the onset of symptoms -- the course then lasts five days.
Remdesivir can be taken within seven days of symptoms setting in, but it is administered intravenously over three days.
- Questions about cost -
The WHO called on Pfizer to "make its pricing and deals more transparent" for Paxlovid.
Lisa Hedman, the WHO's senior advisor on access to medicines, said that radio station NPR reported a full course of Paxlovid costs $530 in the United States. Another source unconfirmed by WHO gave the price of $250 in an upper-middle income country.
Remdesivir meanwhile costs $520, Hedman said, but generic versions made by companies in India sell for $53-$64.
There is also a question mark over whether the virus could build resistance to these treatments.
But earlier this month Pfizer CEO Albert Bourla predicted a bright future for treatments like Paxlovid as people grow tired of getting further booster vaccinations.
Coming under fire for prioritising wealthy countries with its vaccine, Pfizer has agreed to allow some generic drugmakers around the world to make cheaper versions of Paxlovid under a UN-backed scheme.
But on Friday the WHO "strongly recommended" that Pfizer let more generic manufacturers produce the drug and "make it available faster at affordable prices".
K.Thomson--BTB